Clinical Trials
7 trialsNCT03030248 2026-04-15
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Medical College of Wisconsin
Phase 2 Completed
NCT04983901 2026-04-06
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04729322 2025-12-23
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05690048 2025-08-06
FLORA
University Hospital Heidelberg
Phase 2 Recruiting
NCT04025567 2020-03-16
Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT02732327 2017-07-21
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
Forest Laboratories
Phase 2 Terminated